Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 20/20 | 0.56 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19436609 | 0.84 | TNK2 (0.51) | TNK2LRRK2 | |
| SCHEMBL9374322 | 0.81 | TNK2 (0.48) | TNK2MAPK7LRRK2 | |
| SCHEMBL23144753 | 0.80 | TNK2 (0.40) | TNK2MAPK7LRRK2 | |
| SCHEMBL10098691 | 0.80 | MAPK7 (0.56) | TNK2MAPK7LRRK2 | |
| SCHEMBL16065715 | 0.78 | TNK2 (0.40) | TNK2 | |
| SCHEMBL9174480 | 0.78 | RAB9A (0.60) | — | |
| SCHEMBL20628558 | 0.73 | DCLK1 (0.73) | TNK2MAPK7LRRK2 | |
| SCHEMBL20628279 | 0.73 | PIK3CD (0.74) | TNK2MAPK7LRRK2 | |
| SCHEMBL20094145 | 0.72 | LRRK2 (0.50) | TNK2MAPK7LRRK2 | |
| SCHEMBL20094162 | 0.72 | MAPK7 (0.51) | MAPK7LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116375713-B | DCLK1 protein degradation targeting chimeric and application thereof | 中国人民解放军海军军医大学 | 2024-11-19 | — | — | CN | disclosed |
| EP-3528814-B1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | DANA FARBER CANCER INST INC (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-114478539-B | Novel DCLK1 inhibitor and preparation method and application thereof | 中国人民解放军海军军医大学 | 2024-02-02 | — | — | CN | disclosed |
| CN-116375713-A | DCLK1 protein degradation targeting chimeric and application thereof | 中国人民解放军海军军医大学 | 2023-07-04 | — | — | CN | disclosed |
| CN-114478539-A | Novel DCLK1 inhibitor and preparation method and application thereof | 中国人民解放军海军军医大学 | 2022-05-13 | — | — | CN | disclosed |
| EP-3255047-B1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND USES IN TREATING DISORDERS | DANA FARBER CANCER INST INC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-11028089-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3828185-A2 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-10975092-B2 | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2021-04-13 | — | — | US | disclosed |
| US-20200115386-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | Anhui New Star Pharmaceutical Development Co., Ltd . (CN) | 2020-04-16 | — | — | US | disclosed |
| EP-2379559-B1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INST INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170260208-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9701683-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160347755-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9464091-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-05 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| WO-2014160430-A1 | SMALL MOLECULE LRRK2 AND ERK5 INHIBITORS | GEORGETOWN UNIVERSITY (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2010080712-A2 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INSTITUTE (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, BRSK1, TAOK3 | TNK2 85/4885MAPK7 263/4885LRRK2 364/4885 |
| US-10975092-B2 | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | MST1, STK11, MSTN | TNK2 125/4885MAPK7 112/4885LRRK2 143/4885 |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | TNK2 82/4885MAPK7 253/4885LRRK2 340/4885 |
| US-20200115386-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | MST1, STK11, MSTN | TNK2 125/4885MAPK7 112/4885LRRK2 143/4885 |
| US-20160347755-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | TNK2 76/4885MAPK7 263/4885LRRK2 403/4885 |
| US-11028089-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders | CAMK1, CAMKK2, DCLK2 | TNK2 51/4885MAPK7 589/4885LRRK2 162/4885 |
| US-20170260208-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | TNK2 82/4885MAPK7 253/4885LRRK2 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.